113259-81-7

Upstream product

• 158726-94-4 5-morpholino-2-nitrobenzaldehyde dimethyl acetal 
• 110-91-8 morpholine 
• 6628-86-0 5-chloro-2-nitrobenzaldehyde 
• 20357-20-4 5-bromo-2-nitrobenzaldehyde 
• 26908-35-0 5-chloro-2-nitrobenzaldehyde ethylene acetal 
• 587-04-2 m-Chlorobenzaldehyde 
• 395-81-3 5-fluoro-2-nitrobenzaldehyde 
• 1002556-18-4 4-(3-(1,3-dioxolan-2-yl)-4-nitrophenyl)morpholine 
• 13796-06-0 2-nitro-5-chlorobenzaldehyde dimethyl acetal 

Downstream Products

• 927891-84-7 2-amino-5-morpholin-4-ylbenzaldehyde 
• 1312162-94-9 2-((tert-butyldimethylsilyloxy)methyl)-4-morpholinoaniline 
• 1312163-00-0 4-(3-((tert-butyldimethylsilyloxy)methyl)-4-nitrophenyl)morpholine 
• 141928-91-8 5-[[5-(4-Morpholinyl)-2-nitrophenyl]methylene]-2,4-imidazolidinedione 

Relevant academic research and scientific papers

2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS

The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/ or Pyk2 mediated disorder or disease.

Protecting-group-free amination of halogenated nitrobenzaldehyde with palladium catalyst

"One-step" method for the synthesis of secondary aliphatic amine substituted nitrobenzaldehyde was developed. In the presence of Pd catalyst, halogenated nitrobenzaldehyde could be smoothly coupled with secondary aliphatic amine to give the target product

HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS

The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are modulated by a 5-HT5 receptor activity, in particular, for treating neurodegenerative and neuropsychiatric disorders as well as signs, symptoms and dysfunctions.

NEW COMPOUNDS

The present invention encompasses compounds of general Formula (I) wherein R2, R3, Q, W, X, Y and Z are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation

New safety-catch photolabile protecting group

Photolabile protecting groups have proven their usefulness on many occasions. Their versions as linkers are however less attractive, as robustness and real orthogonality become critical issues. Safety-catch systems, where a preliminary activation phase is necessary, circumvent the problem of premature cleavage. In this work, we introduce a new safety-catch photolabile protecting group, whose cleavage requires the simultaneous presence of light and a chemical promoter.

Studies on new platelet aggregation inhibitors 1. Synthesis of 7-nitro-3,4-dihydroquinoline-2(1H)-one derivatives

A series of 6-cyclic aliphatic amino-7-nitro-3,4-dihydroquinoline-2(1H)-ones were prepared and tested for platelet aggregation inhibitory effect, cardiotonic activity and chronotropic activity. These compounds appeared to show selective inhibitory activity against platelet aggregation. Among them, 6-(4-ethoxycarbonylpiperidino)-7-nitro-3,4-dihydroquinoline-2(1H)-one (22f) showed the most potent inhibitory activity and high selectivity. A divergent synthetic route to 6-cyclic aliphatic amino-7-nitro-3,4-dihydroquinoline-2(1H)-one derivatives has also been investigated.